Skip to main content
GetPepWell
Weight Management

Tirzepatide

Physician-supervised compounded dual GIP/GLP-1 therapy for chronic weight management.

Compounded preparation

From$349/mo

Get startedSchedule consultation
Tirzepatide

How it works

Tirzepatide is a 39-amino acid linear peptide that acts as a dual agonist at both GIP and GLP-1 receptors. Its GIP receptor activity (approximately 5x native GIP potency) enhances fat metabolism in adipose tissue, improves insulin sensitivity in peripheral tissues, and may have direct effects on central appetite regulation through hypothalamic GIP receptors. Its GLP-1 receptor activity (comparable to native GLP-1) slows gastric emptying, promotes satiety through hypothalamic POMC neuron activation, and enhances glucose-dependent insulin secretion. The C20 fatty diacid moiety enables albumin binding, extending the half-life to approximately 5 days for once-weekly dosing. The dual mechanism produces additive effects on weight loss and glycemic control that exceed either pathway alone.

Key benefits

  • Dual GIP/GLP-1 mechanism engages two complementary incretin pathways
  • Studied for weight management in finished-product clinical trials
  • Reduction in waist circumference and visceral adiposity reported in finished-product studies
  • Improved insulin sensitivity and glycemic control studied in finished-product diabetes trials
  • Cardiovascular risk-factor improvements (blood pressure, lipids) reported in finished-product data
  • Once-weekly dosing schedule supports adherence
  • Improvements in non-alcoholic steatohepatitis (NASH) biomarkers reported in finished-product studies
  • Potential reduction in obstructive sleep apnea severity reported in finished-product studies

Clinical research

The clinical-trial evidence for tirzepatide weight management was developed for the branded finished products (Mounjaro® and Zepbound®, registered trademarks of Eli Lilly), not for any compounded preparation. The SURMOUNT trial program evaluated finished-product tirzepatide for weight management across adults with and without type 2 diabetes, including comparisons with and without intensive behavioral therapy. The SURPASS trial program studied finished-product tirzepatide in type 2 diabetes alongside multiple active comparators. The compounded preparation dispensed by GetPepWell has not undergone equivalent finished-product efficacy or safety testing; finished-product trial results should be read as evidence about the molecule and its mechanism, not as a guarantee of identical outcomes from the compounded preparation. Your physician will discuss realistic expectations at consultation.

Side effects

  • Nausea (most common, usually diminishes over 4-8 weeks)
  • Diarrhea
  • Decreased appetite (therapeutic but can be pronounced at higher doses)
  • Vomiting, especially during dose escalation periods
  • Constipation
  • Abdominal pain or dyspepsia
  • Injection site reactions
  • Hair thinning (reported in some patients during rapid weight loss)

Contra-indications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Known hypersensitivity to tirzepatide or its excipients
  • History of pancreatitis or active gallbladder disease
  • Pregnancy or planning to become pregnant (discontinue at least 2 months before)
  • Breastfeeding
  • Severe gastrointestinal disease or gastroparesis
  • Diabetic retinopathy requiring active treatment (may worsen transiently)

Drug interactions

  • Insulin and sulfonylureas - significant hypoglycemia risk; dose reduction typically required
  • Oral contraceptives - delayed gastric emptying may reduce bioavailability; use non-oral contraception
  • Warfarin and other anticoagulants - monitor INR closely during initiation
  • Oral medications with narrow therapeutic index - timing of absorption may be altered
  • Acetaminophen - peak absorption delayed; clinical significance is minimal

Storage info

Store unused vials refrigerated at 36-46 degrees F (2-8 degrees C). Do not freeze. After first use, the vial may be stored at room temperature (up to 86 degrees F / 30 degrees C) or refrigerated for up to 21 days. Protect from direct light. Discard 21 days after first puncture. Do not use if the solution is cloudy, discolored, or contains visible particles.

Common questions

Tirzepatide FAQ

Find answers to the most common questions about this treatment.

Interested in Tirzepatide?

Schedule a consultation with a licensed physician to see if this treatment is right for you.

Sign up nowBrowse all products